Immunotherapy With Kidney Disease — What Changes With CKD, Dialysis or a Transplant

Chronic kidney disease does not by itself rule out checkpoint inhibitor immunotherapy. Per NCCN and ASCO guidance it is treated as a monitoring and coordination question, not an automatic exclusion. Your medical oncologist and a nephrologist decide together, case by case, after reading your eGFR trend, your urine report and what your cancer plan actually needs.

That answer surprises most families, because cancer conversations in India usually open with kidney function as a barrier. For conventional chemotherapy it often is one — many of those drugs are small molecules that leave the body through the kidneys, so a low eGFR directly changes what can be given. Checkpoint inhibitor immunotherapy behaves differently. These are large antibody proteins, broken down the way your body breaks down other proteins, so the kidney is not their main exit route.

The practical consequence is that the eligibility discussion moves away from the eGFR number on its own and towards three other things: how stable your kidney function is over time, what else your treatment plan needs alongside the immunotherapy, and whether the monitoring the plan asks for can realistically be kept up between cycles.

No page can tell you that you will be found eligible. That answer comes only from your own team reading your own reports — what this page can do is set out what they will look at, what changes if you go ahead, and which questions are worth asking out loud.

Usually not. Checkpoint inhibitor immunotherapy is given at a dose that is not routinely reduced for a low eGFR, because these antibodies are cleared by ordinary protein breakdown rather than filtered out by the kidneys. What does get adjusted is almost everything given alongside it.

This is the single most useful thing to understand about immunotherapy and kidney disease, and it is the part most often explained wrongly. The dose question and the safety question are separate questions. The immunotherapy itself rarely needs a smaller dose. The plan around it — any chemotherapy partner, contrast dye for scans, hydration, painkillers, and how often blood is checked — is where your kidney numbers do the real work.

The table below sets out the pattern most Indian oncology teams follow. It is a map of the conversation, not a prescription: where your own case sits is decided by your team on your own reports.

Baseline kidney bloods and a urine test before cycle one, then creatinine before every cycle. The purpose is a trend rather than a single reading, so a genuine immune-related change can be separated from an ordinary dehydrated week. Immune kidney inflammation is usually silent, so the blood test is what finds it.

A typical plan for someone who already has reduced kidney function adds these steps to standard immunotherapy monitoring:

The decision is a multidisciplinary one, not a single doctor's call. Your medical oncologist brings the cancer plan. A nephrologist brings your kidney trend, your urine report, your blood pressure and your medicine list. If you have a transplant, your transplant team joins too. The output is a plan, not a verdict handed down from one desk.

Four things carry most of the weight in that discussion. Whether your kidney function is stable or falling, judged on a trend rather than one creatinine reading. Whether your kidneys are already leaking protein or your blood pressure is hard to control, because both change how much a treatment plan can safely ask of you. What your cancer treatment actually needs, and what the realistic alternatives are — including a different treatment, or not treating, where that is genuinely on the table. And whether the monitoring the plan requires is something you and your family can sustain between cycles.

It is worth asking for that reasoning out loud. The most useful question at the consultation is not am I eligible, but what specifically about my kidney function would change your recommendation, and what would we do if it changed during treatment. That question gets you a plan you can act on rather than a yes or no you cannot.

This is a framework for the conversation to have with your treating team. It is not a recommendation for or against immunotherapy in your case, and nothing here promises eligibility.

It is not automatically ruled out, but the honest answer is that the evidence is thin. Patients on dialysis were excluded from most of the trials that established these treatments, so what exists is small published case series rather than large studies. Decisions are made individually, with nephrology involved from the start.

Two practical points come out of that published experience. Because these antibodies are too large to be removed by dialysis, the session does not have to be timed to strip the drug out afterwards — though infusion days and dialysis days are still scheduled around each other so one does not wreck the other. And because a rising creatinine cannot act as an early warning in someone with little residual kidney function, monitoring shifts towards symptoms, electrolytes, fluid balance and the other immune-related side effects instead.

The conversation with a dialysis patient is therefore less about the drug and more about the whole week: how the infusion, the dialysis schedule, the travel and the recovery days fit together, and who you call if something changes in between. Immunotherapy at CION is given as day care, so most of that week is spent at home — which makes the out-of-hours contact one of the details worth pinning down before cycle one rather than after it.

Where the evidence is genuinely immature, your team should say so rather than fill the gap with a number. Ask directly what is known, what is not, and what would make them stop treatment.

Sometimes — but this is the one situation where the risk is specific and serious. Checkpoint inhibitor immunotherapy releases the same immune brakes that anti-rejection medicines are deliberately holding down, so rejection of the transplanted kidney is a recognised risk. The decision is made with your transplant nephrologist before anything is started.

The trade-off is put plainly in that conversation: the possible benefit of treating the cancer, against the possibility of losing the transplanted kidney and returning to dialysis. Some patients weigh it and decide the cancer is the bigger threat. Others decide the graft is. Both are defensible answers, and neither is one an oncologist should settle on your behalf.

If you go ahead, the planning happens up front rather than as you go. Your transplant team decides how your anti-rejection medicines are handled, agrees what rejection monitoring looks like and how often it happens, and sets out in advance what will be done if the graft starts to fail. Those three answers should exist in writing before the first cycle, not be improvised after a blood test surprises everyone.

This page describes how the assessment is made. It is not advice to have, or to refuse, immunotherapy after a transplant — that decision belongs to you, your oncologist and your transplant unit together.

Yes, though it is uncommon. Checkpoint inhibitor immunotherapy can inflame the filtering tissue of the kidney — an immune-related nephritis. NCCN and ASCO irAE guidance recognises it as a distinct adverse event. It usually appears later than skin or bowel reactions, and it is most often found on a blood test rather than felt as a symptom.

What makes it easy to miss is how quiet it is. There is often no pain, no change in how much urine you pass, and no obvious warning until creatinine has already climbed. Occasionally the first hint is new protein in the urine. That is the whole reason your team asks for bloods before every cycle instead of only when you feel unwell — the test is the symptom.

Two everyday medicine groups matter here more than people expect. Anti-inflammatory painkillers and acid-reducing tablets are each associated with kidney inflammation in their own right, and both are extremely commonly taken without telling anyone. Tell your oncology team about everything you take, including anything bought over the counter or prescribed by another doctor, before you start and whenever it changes.

If a rise is picked up, treatment is usually held while the cause is worked out, and medicines to settle the inflammation may be prescribed. All of that belongs to your treating team. Do not start, stop or adjust any medicine for this at home.

Long-term data on how completely kidney function recovers after immune-related nephritis is still maturing. Where the honest answer is that something is not yet well established, your team should say so rather than round it up into a reassurance.

Kidney disease rarely turns up on its own in a medical history. If yours also includes tuberculosis — common in India, and a genuine consideration before any treatment that releases immune brakes — Immunotherapy in Patients With a Previous Tuberculosis History covers what your team screens for and why they ask. Where the immune system itself is the second variable rather than the kidney, Immunotherapy With HIV answers a question that has better evidence behind it than most people assume.

If weight has come up in your consultation alongside the kidney and blood-pressure questions, Immunotherapy in Obese Patients: Does Weight Change Response? separates what is actually known from what gets repeated. And for how immunotherapy is delivered, dosed and monitored across our centres, start with Immunotherapy at CION Cancer Clinics.